Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate

•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2013-11, Vol.100 (2), p.460-472
Hauptverfasser: Kim, Meehyein, Kim, So-Yeon, Lee, Hye Won, Shin, Jin Soo, Kim, Pilho, Jung, Young-Sik, Jeong, Hyeong-Seop, Hyun, Jae-Kyung, Lee, Chong-Kyo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 472
container_issue 2
container_start_page 460
container_title Antiviral research
container_volume 100
creator Kim, Meehyein
Kim, So-Yeon
Lee, Hye Won
Shin, Jin Soo
Kim, Pilho
Jung, Young-Sik
Jeong, Hyeong-Seop
Hyun, Jae-Kyung
Lee, Chong-Kyo
description •EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage. (−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.
doi_str_mv 10.1016/j.antiviral.2013.08.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1676350062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354213002106</els_id><sourcerecordid>1449279494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</originalsourceid><addsrcrecordid>eNqFkMFO3DAQhi1UBMu2r9DupRIcko7tOLaPCBWKtBJComfLcSbFq6yztRMkeALOfUSeBG93S4-cRr_mm5l_fkK-UCgp0PrbqrRh9A8-2r5kQHkJqgRgB2RGlWSFBl1_ILNM1gUXFTsmJymtAKCWWh2RY8a1qKhmM3J7He5940c_hMXQLXzo-gnDk13k3VPKesQYbO-f7F-keVycvjz_OStw43_Zvh-cHdHd-1DwYquz-kgOO9sn_LSvc_Lz8vvdxY9ieXN1fXG-LJwAGAtdARWuRZRIBTptla4Vt8y2CjltZSMElSw3hFX5MwYtdrxpVKVo13Al-Jyc7vZu4vB7wjSatU8Os4eAw5QMrWXN86mavY9WlWZSV7rKqNyhLg4pRezMJvq1jY-GgtlGb1bmLXqzjd6AMtlgnvy8PzI1a2zf5v5lnYGve8AmZ_su2uB8-s9JLTiAztz5jsOc3oPHaJLzGBy2PqIbTTv4d828Asi9pu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449279494</pqid></control><display><type>article</type><title>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kim, Meehyein ; Kim, So-Yeon ; Lee, Hye Won ; Shin, Jin Soo ; Kim, Pilho ; Jung, Young-Sik ; Jeong, Hyeong-Seop ; Hyun, Jae-Kyung ; Lee, Chong-Kyo</creator><creatorcontrib>Kim, Meehyein ; Kim, So-Yeon ; Lee, Hye Won ; Shin, Jin Soo ; Kim, Pilho ; Jung, Young-Sik ; Jeong, Hyeong-Seop ; Hyun, Jae-Kyung ; Lee, Chong-Kyo</creatorcontrib><description>•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage. (−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2013.08.002</identifier><identifier>PMID: 23954192</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>(−)-Epigallocatechin-3-gallate ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral activity ; Antiviral agents ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Catechin - analogs &amp; derivatives ; Catechin - pharmacology ; Cell Line ; Enzyme Inhibitors - pharmacology ; Humans ; Influenza virus ; Medical sciences ; Membrane damage ; Neuraminidase - antagonists &amp; inhibitors ; Orthomyxoviridae - drug effects ; Orthomyxoviridae - physiology ; Pharmacology. Drug treatments ; Viral entry ; Viral Proteins - antagonists &amp; inhibitors ; Virus Internalization - drug effects</subject><ispartof>Antiviral research, 2013-11, Vol.100 (2), p.460-472</ispartof><rights>2013 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</citedby><cites>FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0166354213002106$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27953009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23954192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Meehyein</creatorcontrib><creatorcontrib>Kim, So-Yeon</creatorcontrib><creatorcontrib>Lee, Hye Won</creatorcontrib><creatorcontrib>Shin, Jin Soo</creatorcontrib><creatorcontrib>Kim, Pilho</creatorcontrib><creatorcontrib>Jung, Young-Sik</creatorcontrib><creatorcontrib>Jeong, Hyeong-Seop</creatorcontrib><creatorcontrib>Hyun, Jae-Kyung</creatorcontrib><creatorcontrib>Lee, Chong-Kyo</creatorcontrib><title>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage. (−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.</description><subject>(−)-Epigallocatechin-3-gallate</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral activity</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Catechin - analogs &amp; derivatives</subject><subject>Catechin - pharmacology</subject><subject>Cell Line</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Influenza virus</subject><subject>Medical sciences</subject><subject>Membrane damage</subject><subject>Neuraminidase - antagonists &amp; inhibitors</subject><subject>Orthomyxoviridae - drug effects</subject><subject>Orthomyxoviridae - physiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Viral entry</subject><subject>Viral Proteins - antagonists &amp; inhibitors</subject><subject>Virus Internalization - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFO3DAQhi1UBMu2r9DupRIcko7tOLaPCBWKtBJComfLcSbFq6yztRMkeALOfUSeBG93S4-cRr_mm5l_fkK-UCgp0PrbqrRh9A8-2r5kQHkJqgRgB2RGlWSFBl1_ILNM1gUXFTsmJymtAKCWWh2RY8a1qKhmM3J7He5940c_hMXQLXzo-gnDk13k3VPKesQYbO-f7F-keVycvjz_OStw43_Zvh-cHdHd-1DwYquz-kgOO9sn_LSvc_Lz8vvdxY9ieXN1fXG-LJwAGAtdARWuRZRIBTptla4Vt8y2CjltZSMElSw3hFX5MwYtdrxpVKVo13Al-Jyc7vZu4vB7wjSatU8Os4eAw5QMrWXN86mavY9WlWZSV7rKqNyhLg4pRezMJvq1jY-GgtlGb1bmLXqzjd6AMtlgnvy8PzI1a2zf5v5lnYGve8AmZ_su2uB8-s9JLTiAztz5jsOc3oPHaJLzGBy2PqIbTTv4d828Asi9pu4</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Kim, Meehyein</creator><creator>Kim, So-Yeon</creator><creator>Lee, Hye Won</creator><creator>Shin, Jin Soo</creator><creator>Kim, Pilho</creator><creator>Jung, Young-Sik</creator><creator>Jeong, Hyeong-Seop</creator><creator>Hyun, Jae-Kyung</creator><creator>Lee, Chong-Kyo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T2</scope><scope>7T7</scope><scope>7U2</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20131101</creationdate><title>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</title><author>Kim, Meehyein ; Kim, So-Yeon ; Lee, Hye Won ; Shin, Jin Soo ; Kim, Pilho ; Jung, Young-Sik ; Jeong, Hyeong-Seop ; Hyun, Jae-Kyung ; Lee, Chong-Kyo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>(−)-Epigallocatechin-3-gallate</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral activity</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Catechin - analogs &amp; derivatives</topic><topic>Catechin - pharmacology</topic><topic>Cell Line</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Influenza virus</topic><topic>Medical sciences</topic><topic>Membrane damage</topic><topic>Neuraminidase - antagonists &amp; inhibitors</topic><topic>Orthomyxoviridae - drug effects</topic><topic>Orthomyxoviridae - physiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Viral entry</topic><topic>Viral Proteins - antagonists &amp; inhibitors</topic><topic>Virus Internalization - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Meehyein</creatorcontrib><creatorcontrib>Kim, So-Yeon</creatorcontrib><creatorcontrib>Lee, Hye Won</creatorcontrib><creatorcontrib>Shin, Jin Soo</creatorcontrib><creatorcontrib>Kim, Pilho</creatorcontrib><creatorcontrib>Jung, Young-Sik</creatorcontrib><creatorcontrib>Jeong, Hyeong-Seop</creatorcontrib><creatorcontrib>Hyun, Jae-Kyung</creatorcontrib><creatorcontrib>Lee, Chong-Kyo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Meehyein</au><au>Kim, So-Yeon</au><au>Lee, Hye Won</au><au>Shin, Jin Soo</au><au>Kim, Pilho</au><au>Jung, Young-Sik</au><au>Jeong, Hyeong-Seop</au><au>Hyun, Jae-Kyung</au><au>Lee, Chong-Kyo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>100</volume><issue>2</issue><spage>460</spage><epage>472</epage><pages>460-472</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage. (−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>23954192</pmid><doi>10.1016/j.antiviral.2013.08.002</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2013-11, Vol.100 (2), p.460-472
issn 0166-3542
1872-9096
language eng
recordid cdi_proquest_miscellaneous_1676350062
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects (−)-Epigallocatechin-3-gallate
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral activity
Antiviral agents
Antiviral Agents - pharmacology
Biological and medical sciences
Catechin - analogs & derivatives
Catechin - pharmacology
Cell Line
Enzyme Inhibitors - pharmacology
Humans
Influenza virus
Medical sciences
Membrane damage
Neuraminidase - antagonists & inhibitors
Orthomyxoviridae - drug effects
Orthomyxoviridae - physiology
Pharmacology. Drug treatments
Viral entry
Viral Proteins - antagonists & inhibitors
Virus Internalization - drug effects
title Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T21%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20influenza%20virus%20internalization%20by%20(%E2%88%92)-epigallocatechin-3-gallate&rft.jtitle=Antiviral%20research&rft.au=Kim,%20Meehyein&rft.date=2013-11-01&rft.volume=100&rft.issue=2&rft.spage=460&rft.epage=472&rft.pages=460-472&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2013.08.002&rft_dat=%3Cproquest_cross%3E1449279494%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449279494&rft_id=info:pmid/23954192&rft_els_id=S0166354213002106&rfr_iscdi=true